| Hazard Information | Back Directory | [Uses]
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice[1]. | [Indications]
Palivizumab (Synagis) is a humanized monoclonal antibody
directed against the highly conserved A antigenic
site of the F protein on the surface of RSV. It contains
95% human and 5% murine antibody sequences and
tends to have little immunogenicity in humans.
Palivizumab is composed of the human framework region
of the IgG-1κ-chain joined to the antigen-binding regions of a mouse monoclonal antibody. Palivizumab
neutralizes RSV and inhibits its ability to fuse with host
cell membranes. Resistant strains of RSV have been derived
in vitro but have not been found in clinical isolates
to date. | [Clinical Use]
Palivizumab is used to prevent serious lower respiratory
tract infection due to RSV. It is used only in high-risk
children who are younger than 24 months of age and
have bronchopulmonary dysplasia or chronic lung disease
that required treatment in the previous 6 months.
It is also indicated for premature infants (less than 32
weeks’ gestation) until the age of 6 to 12 months.
Palivizumab can reduce the incidence of RSV-related
hospitalization by approximately half.The safety and efficacy
of palivizumab in the treatment of RSV disease
have not been established. | [Side effects]
Serious adverse reactions caused by palivizumab are
rare.Mild erythema and pain may occur at the injection
site.Although no anaphylactoid reactions have been reported
to date, the possibility of this reaction exists because
palivizumab is a protein. | [in vivo]
Palivizumab (0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.); single dose) can prevent respiratory syncytial virus infection in cotton mice[1].
Palivizumab (0.05 mg/kg; single dose; intranasally administered)can prevent RSV infection in mice[2].
Palivizumab (15 mg/kg; single dose; s.c.) can inhibit RSV induced airway neurogenic inflammation in rats[3]. | Animal Model: | The cotton rat model of RSV infection[1]. | | Dosage: | 0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.) | | Administration: | Intramuscular injection (i.m.) or intravenous injection (i.v.); single dose | | Result: | Reduced virus replication and did not cause RSV infection or pathological increase in both initial and secondary attacks. |
| Animal Model: | BALB/c mice[2]. | | Dosage: | 0.05 mg/kg | | Administration: | Intranasally administered; single dose | | Result: | Reduced the RSV load. |
| Animal Model: | Capsaicin-induced neurogenic inflammation in the airways of rats[3]. | | Dosage: | 15 mg/kg | | Administration: | Subcutaneous injection (s.c.); single dose | | Result: | Reduced neurogenic extravasation and neurogenic inflammation. |
| [storage]
Store at -20°C | [References]
[1] Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24. DOI:10.1086/514115
[2] Jacobino SR, et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs. 2018 Apr;10(3):453-462. DOI:10.1080/19420862.2018.1433974
[3] Piedimonte G, et al. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res. 2000 Mar;47(3):351-6. DOI:10.1203/00006450-200003000-00011 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|